Meftal, containing mefenamic acid, is commonly prescribed for menstrual cramps and rheumatoid arthritis...
Digital Desk: The Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert urging healthcare professionals and patients to monitor adverse reactions associated with the widely-used painkiller Meftal. Meftal, containing mefenamic acid, is commonly prescribed for menstrual cramps and rheumatoid arthritis.
The alert, released on November 30, follows a preliminary analysis of adverse drug reactions reported to the Pharmacovigilance Programme of India (PvPI) database. The findings revealed instances of drug reactions associated with eosinophilia and systemic symptoms (DRESS) syndrome.
Healthcare professionals and consumers are advised to closely monitor the possibility of such adverse drug reactions (ADRs) linked to Meftal usage. In case of encountering such reactions, individuals are encouraged to promptly report the matter to the national coordination centre of the PvPI under the commission. This can be done by filing a form on the official website, www.ipc.gov.in, or through the Android mobile app ADR PvPI. Additionally, a helpline is available at 1800-180-3024.
As an autonomous institution under the Ministry of Health, the IPC plays a crucial role in setting standards for all drugs manufactured, sold, and consumed in India. The safety alert underscores the commission's commitment to ensuring the well-being of patients and the efficacy of pharmaceutical products in the country.
Continue Reading
